Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data

Emilie Sbidian; Myriam Mezzarobba; Jason Shourick; Cécile Billionnet; Joël Coste; Alain Weill; Jérémie Rudant; Olivier Chosidow; Loes Hollestein; Tamar Nijsten

doi:10.2340/00015555-3765

Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data

Emilie Sbidian^*, Myriam Mezzarobba, Jason Shourick, Cécile Billionnet, Joël Coste, Alain Weill, Jérémie Rudant, Olivier Chosidow, Loes Hollestein, Tamar Nijsten

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

37 Downloads (Pure)

Abstract

Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 countries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.

Original language	English
Article number	adv00473
Journal	Acta Dermato-Venereologica
Volume	101
Issue number	6
DOIs	https://doi.org/10.2340/00015555-3765
Publication status	Published - 2021

Bibliographical note

Funding Information:
This study was approved by the French data protection agency Commission Nationale de l’Informatique et des Libertés (regulatory decision DE-2015-165). ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers.

Funding Information:
ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers.

Publisher Copyright:
© 2021, Medical Journals/Acta D-V. All rights reserved.

Access to Document

10.2340/00015555-3765Licence: CC BY-NC

Choice of Systemic Drugs for the Management of Moderate-tosevere PsoriasisFinal published version, 888 KBLicence: CC BY-NC

Cite this

Sbidian, E., Mezzarobba, M., Shourick, J., Billionnet, C., Coste, J., Weill, A., Rudant, J., Chosidow, O., Hollestein, L., & Nijsten, T. (2021). Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data. Acta Dermato-Venereologica, 101(6), Article adv00473. https://doi.org/10.2340/00015555-3765

@article{8a87b8294d714fd090f9e230b050e763,

title = "Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data",

abstract = "Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 countries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.",

author = "Emilie Sbidian and Myriam Mezzarobba and Jason Shourick and C{\'e}cile Billionnet and Jo{\"e}l Coste and Alain Weill and J{\'e}r{\'e}mie Rudant and Olivier Chosidow and Loes Hollestein and Tamar Nijsten",

note = "Funding Information: This study was approved by the French data protection agency Commission Nationale de l{\textquoteright}Informatique et des Libert{\'e}s (regulatory decision DE-2015-165). ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers. Funding Information: ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers. Publisher Copyright: {\textcopyright} 2021, Medical Journals/Acta D-V. All rights reserved.",

year = "2021",

doi = "10.2340/00015555-3765",

language = "English",

volume = "101",

number = "6",

}

Sbidian, E, Mezzarobba, M, Shourick, J, Billionnet, C, Coste, J, Weill, A, Rudant, J, Chosidow, O, Hollestein, L & Nijsten, T 2021, 'Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data', Acta Dermato-Venereologica, vol. 101, no. 6, adv00473. https://doi.org/10.2340/00015555-3765

TY - JOUR

T1 - Choice of systemic drugs for the management of moderate-to-severe psoriasis

T2 - A cross-country comparison based on national health insurance data

AU - Sbidian, Emilie

AU - Mezzarobba, Myriam

AU - Shourick, Jason

AU - Billionnet, Cécile

AU - Coste, Joël

AU - Weill, Alain

AU - Rudant, Jérémie

AU - Chosidow, Olivier

AU - Hollestein, Loes

AU - Nijsten, Tamar

N1 - Funding Information: This study was approved by the French data protection agency Commission Nationale de l’Informatique et des Libertés (regulatory decision DE-2015-165). ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers. Funding Information: ES was supported by the French Society of Dermatology and by the French Teachers College, section dermatology CEDEF. CB, MM, AW, JR were employees of the French National Health Insurance Fund. The present paper represents the opinions of the authors and does not necessarily reflect the position of their employers. Publisher Copyright: © 2021, Medical Journals/Acta D-V. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 countries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.

AB - Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 countries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.

UR - http://www.scopus.com/inward/record.url?scp=85109054640&partnerID=8YFLogxK

U2 - 10.2340/00015555-3765

DO - 10.2340/00015555-3765

M3 - Article

C2 - 33585948

AN - SCOPUS:85109054640

SN - 0001-5555

VL - 101

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 6

M1 - adv00473

ER -

Choice of systemic drugs for the management of moderate-to-severe psoriasis: A cross-country comparison based on national health insurance data

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this